Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AC Immune (ACIU) Other Non Operating Income: 2020-2025

Historic Other Non Operating Income for AC Immune (ACIU) over the last 6 years, with Sep 2025 value amounting to -$15,001.

  • AC Immune's Other Non Operating Income rose 99.51% to -$15,001 in Q3 2025 from the same period last year, while for Sep 2025 it was -$764,917, marking a year-over-year increase of 86.48%. This contributed to the annual value of -$1.8 million for FY2024, which is 10.30% down from last year.
  • As of Q3 2025, AC Immune's Other Non Operating Income stood at -$15,001, which was up 99.44% from -$2.7 million recorded in Q2 2025.
  • AC Immune's Other Non Operating Income's 5-year high stood at $2.2 million during Q4 2024, with a 5-year trough of -$3.1 million in Q3 2024.
  • Its 3-year average for Other Non Operating Income is -$583,708, with a median of -$55,139 in 2023.
  • Within the past 5 years, the most significant YoY rise in AC Immune's Other Non Operating Income was 3,451.49% (2024), while the steepest drop was 15,460.20% (2024).
  • AC Immune's Other Non Operating Income (Quarterly) stood at -$405,604 in 2021, then soared by 72.10% to -$113,144 in 2022, then slumped by 1,361.70% to -$1.7 million in 2023, then skyrocketed by 235.63% to $2.2 million in 2024, then skyrocketed by 99.51% to -$15,001 in 2025.
  • Its Other Non Operating Income stands at -$15,001 for Q3 2025, versus -$2.7 million for Q2 2025 and -$324,777 for Q1 2025.